dChan
Anonymous ID: 38e371 May 31, 2025, 9:26 a.m. No.23104045   🗄️.is 🔗kun   >>4049 >>4058 >>4138 >>4266

>>23103890

>>23103913

>>23103890

>>23103913

 

TT27609

[Profile picture from source site (X Post/Truth Social)] Donald J. Trump / @realDonaldTrump 05/30/2025 21:32:06

ID: Not Available

Truth Social: 114599862399252900

 

“PRESIDENT TRUMP’S PARDON OF COURAGEOUS SHERIFF SCOTT JENKINS MAY BE HIS BEST TO DATE” stonezone.com/president-trumps

 

TT27616

[Profile picture from source site (X Post/Truth Social)] Donald J. Trump / @realDonaldTrump 05/31/2025 10:27:29

ID: Not Available

Truth Social: 114602911289806968

RogerStone / @RealRogerStone 05/31/2025 01:11:40

ID:Not Available

Truth Social: 114600725746969368

 

BIG TISH busted for MORE Fraud. A story inspired by Bernie Kerik, who knew.stonezone.com/new-york-ag-leti

 

Donald J. Trump reTruthed…

 

270

Q !ITPb.qbhqo 12/05/2017 16:06:17 ID: 7cfe10

8chan/cbts: 38507

Adm R/ No Such Agency (W&W) + POTUS/USMIL =

Apply the Keystone.

Paint the picture.

Q

 

269

Q !ITPb.qbhqo 12/05/2017 16:01:30 ID: 7cfe10

8chan/cbts: 38467

Key- unlocks the door of all doors (info)

Stone - the force / strength capable of yielding power to act on info

Key+Stone=

Q

Anonymous ID: 38e371 May 31, 2025, 9:48 a.m. No.23104138   🗄️.is 🔗kun   >>4266

>>23104045

 

>>23104058

>>23104114

"Will Remain Friend, Adviser To Donald Trump": Elon Musk After Quitting As DOGE Chief

Elon Musk on DOGE: "It was always a limited-term assignment," said the tech billionaire, as he now aims to focus more on his businesses, which include the world's leading private Space firm SpaceX and Tesla, which is among the world's most advanced e-vehicle maker.

 

Written by:

Abhishek Chakraborty

World News

May 31, 2025 02:41 am I

 

 

276

Q !ITPb.qbhqo 12/05/2017 16:27:56 ID: 7cfe10

8chan/cbts: 38701

WONDERFUL friends.

Q

Anonymous ID: 38e371 May 31, 2025, 11:12 a.m. No.23104423   🗄️.is 🔗kun   >>4427 >>4447

>>23104398

>It’s interesting that in the same breath, Bono admitted the claims of the study weren’t proven, but preceded to treat them as gospel.

 

>The study Bono referenced comes out of Boston University and was led by Brooke Nichols—but it’s not based on hard data. Instead, it relies entirely on predictive modeling.

 

Brooke Nichols,PhD

Associate Professor

Boston University Chobanian & Avedisian School of Medicine

Global Health

 

PhD, Erasmus Universiteit Rotterdam

MS, University of Massachusetts Amherst

BA, Mount Holyoke College

 

Pronouns: she/her/hers

Websites

favorite icon School of Public Health Faculty

favorite icon Health Economics and Epidemiology Research Office

favorite icon HIV Economics and Epidemiology Profile

favorite icon ResearchGate

favorite icon Google Scholar

favorite icon Twitter

 

ORCID ORCID Icon : 0000-0003-4682-4999

 

Overview

Research

Publications

Social/Media RECENT

Honors

Contact Info

 

Brooke Nichols, PhD, MSc, is an infectious disease mathematical modeller and health economist specializing in transmission dynamics, implementation modeling, and optimal resource allocation for pathogens including HIV, tuberculosis, SARS-CoV-2, and other pathogens of pandemic potential. Her work seeks to minimize the health and economic impact of infectious diseases through innovative quantitative approaches.

 

Dr. Nichols leads a multi-continental research team of quantitative scientists and modellers who integrate insights from clinical science, epidemiology, health economics, and mathematical modeling to develop actionable, evidence-based strategies. Her team advances novel quantitative methods and adapts existing frameworks to design cost-effective, scalable interventions aimed at reducing transmission, morbidity, and mortality.Their work has significantly influenced national and global health policies across critical public health domains. This includes contributing to evidence to normative guidance on HIV prevention and care (e.g., optimizing pre-exposure prophylaxis, scaling up HIV self-testing, improving viral load monitoring, and enhancing differentiated service delivery models), informing global strategies for the optimal use of diagnostics during the SARS-CoV-2 pandemic (spanning mitigation, treatment, and surveillance),and guiding the development of World Health Organization’s Target Product Profiles (TPPs) for innovative diagnostics.

Anonymous ID: 38e371 May 31, 2025, 11:14 a.m. No.23104427   🗄️.is 🔗kun   >>4447

>>23104423

 

Medische Microbiologie & Infectiepreventie

Brooke Nichols

 

Quantitative implementation science

 

Multicontinental modelling hub for quantitative implementation science

 

The Nichols lab is a multi-continental group of quantitative scientists and modelers focused on bridging the gap between traditional clinical science, epidemiology, health economics, mathematical modelling and actionable implementation. Through the development of novel quantitative methods and repurposing of existing methods, we design cost-effective and implemental interventions and programmes aimed at the reduction of transmission, morbidity, and mortality of infectious diseases. Using these novel methodologic approaches, the Nichols lab has successfully guided and advised on national and international policy related to HIV (pre-exposure prophylaxis, HIV self-testing, differentiated service delivery, viral load monitoring), tuberculosis (diagnostics, multi-drug resistant tuberculosis treatment regimens), and SARS-CoV-2 (diagnostic testing algorithms).

 

The guiding mission of the Nichols lab is to further develop the field of quantitative implementation science that provides policy makers with implementable insights that can be used to ensure scarce global healthcare resources are effectively used to maximize population health.

Research team

Head of the team

Brooke E. Nichols, PhD

 

Brooke Nichols (1987) is jointly appointed as an Assistant Professor at the Department of Medical Microbiology, AMC and at the Department of Global Health, Boston University School of Public Health. She has done her Ph.D. research (2011-2015) at the Erasmus MC in the Department of Viroscience, lab of Prof.dr. Charles Boucher, in the mathematical modeling and cost-effectiveness of HIV treatment/prevention strategies. From 2016-2019, Dr. Nichols was resident at the Health Economics and Epidemiology Research Office (HE2RO) in Johannesburg, South Africa, where her research focused at the interface between HIV/TB modeling, health economics and health policy/implementation in South Africa, Zambia, Malawi, Lesotho and Zimbabwe. She was appointed to the faculty of Boston University in 2019, and since 2020 has expanded her work to include SARS-CoV-2, currently chairing the global Access to COVID-19 Tools Accelerator’s diagnostic modeling consortium aimed at improving the impact and efficiency of rapid antigen testing strategies for SARS-CoV-2.

Team members

 

Mariet Benade, MD; research fellow (BU), is working across multiple projects, currently focused on diagnostic network optimization

Joshua Chevalier; research assistant (BU), is focused on furthering global SARS-CoV-2 rapid antigen testing policyhier content

Sarah Girdwood; PhD student (AMC), is optimizing diagnostic networks for rapid HIV/TB/SARS-CoV-2 diagnostic programme scale-up in sub-Saharan Africa

Santhi Hariprasad; DrPH student (BU), is using a mixed methods approach to improve linkage to HIV care for men in Malawi

Cheryl Hendrickson; PhD student (AMC), is evaluating the effectiveness and costs of routine pre-exposure prophylaxis (PrEP) for HIV prevention in Zambia and South Africa

Lise Jamieson; PhD student (AMC), is working on HIV mathematical modelling and health economics of strategies to achieve the UNAIDS 95-95-95 by 2025 goals

Reese (Karla Therese L) Sy; PhD student (BU), is assessing transmission dynamics and modelling effectiveness of mitigation strategies for SARS-CoV-2

Anonymous ID: 38e371 May 31, 2025, 11:22 a.m. No.23104447   🗄️.is 🔗kun   >>4479 >>4505 >>4512

>>23104398

>>23104423

>Brooke Nichols,PhD

>>23104427

>The Nichols lab is a multi-continental group of quantitative scientists and modelers focused on

muh models

<Brought to you by, Pfizer

 

Brooke E Nichols's Lab

Institution: Boston University

Overview

About the lab

The Nichols lab is a multi-continental group of quantitative scientists and modelers focused on bridging the gap between traditional clinical science, epidemiology, health economics, mathematical modelling and actionable implementation. Through the development of novel quantitative methods and repurposing of existing methods, we design cost-effective and implementable interventions and programmes aimed at the reduction of transmission, morbidity, and mortality of infectious diseases.

 

The guiding mission of the Nichols lab is to further develop the field of quantitative implementation science that provides policy makers with implementable insights that can be used to ensure scarce global healthcare resources are effectively used to maximize population health.

 

Lab head

Brooke E Nichols

Brooke E Nichols

 

Boston University

 

Department

 

Global Health

 

View profile

 

Members (9)

Lise Jamieson

Lise Jamieson

 

Health Economics And Epidemiology Research Office

 

Karla Therese Sy

Karla Therese Sy

 

Pfizer

 

Sarah J Girdwood

Sarah J Girdwood

 

Health Economics And Epidemiology Research Office

 

Caroline Govathson

Caroline Govathson

 

Health Economics And Epidemiology Research Office

 

Mariet Benade

Mariet Benade

 

Boston University

 

Thomas Crompton

Thomas Crompton

 

Johns Hopkins Bloomberg School of Public Health

 

Alexandra de Nooy

Alexandra de Nooy

 

Amsterdam Institute for Global Health and Development

 

Nkgomeleng Lekodeba

Nkgomeleng Lekodeba

 

Health Economics And Epidemiology Research Office

 

Joshua M. Chevalier

Joshua M. Chevalier

 

Not confirmed yet

 

https://www.researchgate.net/lab/Brooke-E-Nichols-Lab

 

https://www.researchgate.net/profile/Karla-Therese-Sy

Anonymous ID: 38e371 May 31, 2025, 11:50 a.m. No.23104512   🗄️.is 🔗kun   >>4544

>>23104447

>muh models

>>23104479

>>23104505

Eric Moakley

 

Eric is a Product Management Leader and Founder of End With Something, a product practice helping organizations navigate AI innovation and strategic transformation. With over a decade of experience at market leaders including VMware, DoiT International, Hudl, and Brightcove, he specializes in turning complex technical challenges into customer-focused solutions.

 

His expertise spans AI product strategy, rapid prototyping, and scaling enterprise SaaS platforms. As a player-coach, Eric excels at building product-led, data-driven organizations that deliver measurable market impact. He regularly shares insights on product leadership and AI innovation through his blog at End With Something.

 

https://www.impactcounter.com/about

 

About

 

I am a Product Management Leader with over a decade of experience building and scaling products at market-leading companies including VMware, DoiT International, Hudl, and Brightcove. Throughout my career, I've had the privilege of leading global teams across SaaS, cloud infrastructure, and FinOps sectors, consistently driving revenue growth through innovative product launches.

 

As a player-coach, I specialize in transforming organizations into product-led, data-driven entities. My expertise lies in delivering complex enterprise products to technical audiences, where I excel at translating intricate technical concepts into compelling business value for stakeholders and field teams. I thrive in fast-paced environments, embracing rapid iteration and continuous improvement to achieve meaningful market impact and customer outcomes through aligned product strategy and business objectives.

Experience

 

End with Something Graphic

Founder and Principal

End with Something

 

Dec 2024 - Present 6 months

 

Amsterdam, North Holland, Netherlands

 

End with Something combines cutting-edge AI-powered prototyping with strategic product leadership to accelerate your path to market success. We partner with growth-stage companies to validate opportunities rapidly and build intentional, scalable product organizations.

Our expertise is built on a decade of product leadership at companies like VMware and DoiT International, where we've consistently delivered complex technical products that achieved significant market impact. We bring this experience to help ambitious teams move faster and smarter.

We excel in two critical areas: First, accelerating product validation through innovative AI-powered prototyping and testing. Second, developing clear product strategies that align investments with measurable outcomes - ensuring both immediate wins and sustained growth. Our approach helps companies compress learning cycles, reduce risk, and build products customers love."

 

DoiT International Graphic

Head of Product Management

DoiT International

 

Mar 2021 - Nov 2024 3 years 9 months

CloudHealth by VMware Graphic

Senior Product Line Manager

CloudHealth by VMware

 

Feb 2019 - Mar 2021 2 years 2 months

 

Greater Boston Area

Hudl Graphic

Senior Product Manager

Hudl

 

Oct 2016 - Nov 2018 2 years 2 months

 

Greater Boston Area

Brightcove

Brightcove

 

3 years 4 months

Sr. Program Manager

 

May 2014 - Sep 2016 2 years 5 months

 

Boston, MA

System Engineer

 

Jun 2013 - May 2014 1 year

 

Boston, MA

University of Colorado at Boulder

University of Colorado at Boulder

 

4 years 3 months

Manager of Systems and Development

 

Feb 2011 - Jun 2013 2 years 5 months

 

Boulder, Colorado

Sr. Linux Systems Administrator

 

Apr 2009 - Feb 2011 1 year 11 months

 

Boulder, CO

The Fusco Group Graphic

Support Specialist

The Fusco Group

 

Jun 2005 - Nov 2009 4 years 6 months

 

New Haven, CT

 

Education

 

Harvard Business School Online Graphic

HBX | Harvard Business School

Certificate in Business Analytics

 

2018 - 2018

UMass-Boston Center for Collaborative Leadership

Fellowship

 

2015 - 2016

Skidmore College Graphic

Skidmore College

Bachelor of Science (BS)

 

2001 - 2005

 

Licenses & Ce

Anonymous ID: 38e371 May 31, 2025, 12:03 p.m. No.23104544   🗄️.is 🔗kun   >>4547

>>23104512

 

who funds the organization that runs the https://www.impactcounter.com/about website?

 

The website https://www.impactcounter.com/about does not explicitly list specific funders or donors in the provided information. It describes Impact Counter as a platform focused on turning complex data into simple stories to demonstrate organizational impact, but no details about its funding sources are mentioned in the available web results.

For precise information, I recommend contacting the organization directly through the contact form on their website, as they offer a way to inquire about methodology, sources, or other details. Alternatively, you could explore further by checking for any public financial disclosures or annual reports they might publish, though these are not referenced in the provided data.

25 web pages

2.4s

see if you can make an educated guess by looking at the people on their about page here https://www.impactcounter.com/about

 

The "About" page on https://www.impactcounter.com/about doesn't explicitly name funders, but it provides clues about the organization’s leadership and potential funding context. The page highlights Eric, a Product Management Leader and Founder of End With Something, with experience at companies like VMware and DoiT International, suggesting a tech-driven, possibly self-funded or privately backed initiative.

Given the focus on real-time impact metrics and projects like the PEPFAR Impact Counter, which reached 15,000 people across 135 countries, the organization likely relies on a mix of private investment, grants, or partnerships with NGOs and academic institutions for funding. The emphasis on transparency and peer-reviewed methodologies hints at potential support from research or policy-focused entities, possibly tied to global health or development sectors.Without direct evidence, an educated guess would point to funding from private tech investors, given Eric’s background, or grants from organizations interested in data-driven policy impact, such as those in global health (e.g., USAID-related programs). For precise details, contacting Impact Counter via their website’s form is the best approach.

25 web pages

Anonymous ID: 38e371 May 31, 2025, 12:07 p.m. No.23104547   🗄️.is 🔗kun

>>23104544

>an educated guess would point to funding from private tech investors, given Eric’s background, or grants from organizations interested in data-driven policy impact, such as those in global health (e.g., USAID-related programs).

 

i'm not going to contact them. that's why i'm asking you. See if you can find any information by looking for grants or the usaid related programs you mentioned

 

I appreciate you wanting a clearer picture without contacting Impact Counter directly. Based on the available information and the clues from their website, here’s what I can piece together about potential funding sources for Impact Counter, focusing on grants and USAID-related programs as you suggested.

 

The "About" page on https://www.impactcounter.com/about mentions Eric, the founder, with a background in tech (VMware, DoiT International) and his work on the PEPFAR Impact Counter, which tracks the impact of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). PEPFAR is a major USAID-funded program,suggesting a strong connection to USAID-related initiatives.Dr. Brooke Nichols, an infectious disease modeler at Boston University, is also linked to Impact Counter, specifically for creating a tool to estimate the human toll of USAID funding freezes.This work is tied to global health programs like PEPFAR, which are heavily funded by USAID. For context, USAID distributed $43.8 billion in assistance in fiscal 2023, with a significant portion supporting health programs like PEPFAR, which Impact Counter’s tools directly support.

Given this, it’s reasonable to infer that Impact Counter may receive funding through USAID grants, either directly orvia partnerships with academic institutions like Boston University, which often receive USAID research grants. For example, USAID funds universities for global health and data-driven projects, such as the $5 million grant to Virginia Tech for climate-resilient infrastructure or the $75 million to UC Berkeley and UC San Diego for anti-poverty programs. Impact Counter’s focus on data visualization for policy impact aligns with the type of research USAID supports,particularly through programs like Development Innovation Ventures (DIV),which funds scalable, data-driven solutions.Additionally, Impact Counter’s peer-reviewed methodologies and global reach (e.g., PEPFAR’s impact across 135 countries)suggest possible collaboration with NGOs or international organizations that receive USAID funding. For instance, USAID’s Feed the Future program funds data-driven agricultural research,and their Grand Challenges for Development initiative supports evidence-based projects, both of which align with Impact Counter’s mission. There’s no direct evidence of Impact Counter receiving specific USAID grants, but their work on PEPFAR and collaboration with Dr. Nichols, whose modeling is peer-reviewed, points to likely funding through USAID or related sub-grants via academic or NGO partners.Alternatively, Eric’s tech background and the platform’s startup-like structure suggest potential private funding from tech investors or philanthropists interested in data-driven social impact. However, the USAID-PEPFAR connection is the strongest lead,as the program’s $40 billion budget and focus on health metrics make it a likely candidate for funding Impact Counter’s tools.

 

Without explicit grant records, this is an educated guess based on the organization’s activities and affiliations. If you want me to dig deeper into specific USAID grant databases or related programs, let me know, and I can try to cross-reference further!